Aim: To explore the molecular mechanisms underlying the cholesterol-lowering effect of a Ginkgo biloba extract (GBE). Methods: Enzyme activity, cholesterol flux and changes in gene expression levels were assessed in cultured hepatocytes treated with GBE or lovastatin. Results: GBE decreased the total cholesterol content in cultured hepatocytes and inhibited the activity of HMG-CoA reductase, as determined by an in vitro enzyme activity assay. In addition, GBE decreased cholesterol influx, whereas lovastatin increased cholesterol influx. GBE treatment induced significant increases in the expression of cholesterogenic genes and genes involved in cholesterol metabolism, such as SREBF2, as determined by cDNA microarray and real-time RT-PCR. Furthermore, INSIG2, LDLR, LRP1, and LRP10 were differentially regulated by GBE and lovastatin. The data imply that the two compounds modulate cholesterol metabolism through distinct mechanisms. Conclusion: By using a gene expression profiling approach, we were able to broaden the understanding of the molecular mechanisms by which GBE lowers cellular cholesterol levels. Specifically, we demonstrated that GBE exhibited dual effects on the cellular cholesterol pool by modulating both HMG-CoA reductase activity and inhibiting cholesterol influx.
Introduction
Ginkgo biloba extract (GBE) is being increasingly used as a dietary supplement for the treatment of a variety of neurological and cardiovascular disorders. The main active components of the standard GBE are flavonol glycosides (~24% total volume) and terpene lactones (~6%) [1] . The mixture of biologically active ingredients present in GBE has pleiotropic physiological effects, including the inhibition of amyloidformation [2, 3] , antioxidant activity [4, 5] , anti-apoptosis activity [6] , effects on vasodilation [7] and inhibition of platelet aggregation [8, 9] . Recently, studies have shown that GBE modulates the metabolism of cholesterol. GBE decreased the blood cholesterol level in rats and rabbits fed a cholesterol-enriched diet [10] [11] [12] . In humans, GBE ingestion reduces the formation and size of atherosclerotic nanoplaques in high-risk cardiovascular patients and attenuates risk factors, including oxidized low-density lipoprotein (oxLDL)/low density lipoprotein (LDL) and lipoprotein Lp(a) [13] . These observations reveal the modulating effect of GBE on cholesterol metabolism; however, the underlying mechanisms remain undefined.
The liver is the major source of endogenous cholesterol biosynthesis and is largely responsible for the maintenance of blood cholesterol homeostasis. Therefore, we used two cultured human hepatocellular carcinoma cell lines, HepG2, and SK-HEP-1, in the present study to evaluate the cholesterollowering effect of GBE. In addition, we used lovastatin, a well-known cholesterol-lowering medication, as our positive control. To investigate the mechanisms underlying the Molecular mechanisms underlying the cholesterollowering effect of Ginkgo biloba extract in hepatocytes: a comparative study with lovastatin 
Materials and methods
Cell culture and treatment GBE was provided by XingLing Pharmaceutical Co (Shanghai, China) as a standardized product that contains ~24% flavonol glycosides, ~6% terpene lactones (ginkgolides, bilobalide), and less than ~5 ppm ginkgolic acid. HepG2 cells were maintained in Minimum Essential Medium (MEM, Invitrogen) with 10% fetal bovine serum (FBS) (JRH Biosciences). Cells were seeded in 6-well plates at a density of 4×10 5 cells per well. When the cells were about 70% confluent, the medium was replaced with medium containing 2% FBS for drug treatment experiments. For dose-response experiments, a variety of concentrations of GBE (50, 100, and 200 µg/mL) were used, and the cells were treated for 24 h. For time course experiments, cells were treated for different times (6, 12, 24 , and 48 h) with either 200 µg/mL of GBE or 0.5 μmol/L lovastatin. Control cells were treated with 0.1% DMSO (the vehicle) for the longest treatment time in the experiment. Treatments were identical for both the SK-HEP-1 and the HepG2 cell lines, with the exception that SK-HEP-1 cells were cultured in Dulbecco's modified Eagle's medium (DMEM, Invitrogen).
Cellular cholesterol measurement
Cellular total cholesterol was extracted as previously reported [14] with slight modifications. Briefly, cells were harvested and washed twice with PBS, followed by resuspension in 1 mL isopropanol and sonication for 20 min at 4 °C. After centrifugation at 9000 ×g for 10 min at 4 °C, the supernatant was evaporated under a vacuum and the pellet was resuspended in 20 μL isopropanol for cellular cholesterol measurement. The cholesterol was measured colorimetrically using a Total Cholesterol Detection Kit (Jiemen Bio-Tech, Shanghai, China). Additionally, the sediment fractions were lysed using a Mammalian Cell Extraction Kit (BioVision). Total protein levels were quantified by the Bradford method.
HMG-CoA reductase enzymatic activity assay
The activity of HMG-CoA reductase was measured according to a previously published method [15] with slight modifications. Briefly, microsomes were prepared from the livers of rats. The assay was performed in a total volume of 120 µL containing 500 nmol NADPH (dissolved in 0.1 mol/L triethanolamine and 10 mmol/L EDTA) and 100 µg of microsomes. After a 5 min preincubation at 37 °C, 5.17 nmol [
14 C]HMG-CoA (GE Healthcare), with or without GBE or lovastatin, was added to the system (final concentration 38.3 μmol/L and 2.14 GBq/ mmol, respectively). After a 15 min incubation at 37 °C, the reaction was terminated by the addition of 30 µL of 6 mol/L HCl. The samples were incubated for 15 min at 37 °C to allow complete lactonization of the mevalonic acid, followed by centrifugation at 9000×g for 10 min. The supernatants were spotted onto silica gel GF254 TLC plates, and the chromatograms were developed in benzene-acetone 1:l (v/v). [ 14 C]MVA lactone (GE Healthcare) was used as a reference. The [ 14 C] radioactivity was determined with a liquid scintillation counter (LS6500, Beckman-Coulter). HMG-CoA reductase activity was calculated as µmol of mevalonate generated per minute per mg of microsomes at 37 °C.
Cholesterol influx and efflux assay
Cholesterol influx and efflux assays were carried out according to the methods described by Yao et al [10] . For the cholesterol influx measurements, 2×10
5 HepG2 cells were seeded in 24-well plates and cultured in MEM plus 10% FBS. When the cells reached 75%−80% confluence, the medium was replaced with 0.5 mL MEM containing 2% FBS and 0.2 μCi [1α,2α(n)- H] cholesterol (GE Healthcare) and the presence or absence of either various concentrations of GBE (50, 100, and 200 μg/mL) or lovastatin (0.5 μmol/L). After 24 h of treatment, the cells were washed with PBS twice and lysed in 200 µL of 0.1 mol/L NaOH. Radioactivity was measured by a liquid scintillation counter (LS6500, Beckman-Coulter). Protein levels were quantified by the Bradford method.
For the efflux assay, 2×10 5 HepG2 cells were seeded in 24-well plates and cultured with MEM plus 10% FBS and 0.2 μCi [1α,2α(n)-
3 H]cholesterol in each well for 48 h. After incubation, the cells were washed twice with MEM plus 10% FBS and FBS-free medium. Then, the cells were treated with the indicated concentrations of GBE and lovastatin in 0.5 mL MEM plus 2% FBS for 24 h. A volume of 200 µL of medium was used to determine the level of radioactivity. Protein levels were quantified as described above.
cDNA microarray
After the time course experiments, cells were collected and total RNA was extracted using TRIzol reagent (Invitrogen), followed by purification on an RNeasy column (Qiagen) and quantified by UV absorption (Nanodrop). RNA quality was assessed with a 2100 Bioanalyzer and the RNA 6000 LabChipR (Agilent Technologies). The SBC homemade human cDNA microarray (Shanghai, China) contains 15552 spots, including 768 controls and 14784 probes. The probes represent 10379 known genes and 3022 ESTs. The microarray was made as previously described [16] . An Agilent Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies) was used for RNA linear amplification following the manufacturer's protocol. RNA samples from three wells of the vehicle treated group were pooled and used as a reference to label Cy3 (GE Healthcare). RNA from the drug treated cells was isolated in triplicate and labeled with Cy5 individually. Cy3-and Cy5-labeled cRNA pools were mixed to hybridize to the microarrays. Hybridization and washes were performed using a standard protocol, followed by scanning on a Axon 4000B Scanner (Axon Instruments) [17] . [18] . Only genes present in greater than 80% of the samples were filtered out for further analysis. A total of 9510 genes/ESTs were selected out. The log2 ratio of each gene/EST is available at the following Web site: www. shbiochip.com/research/GBE/HepG2. Principal Components Analysis (PCA) was applied to distinguish between different groups. Gene expression profiling at each time point was analyzed with Significance Analysis of Microarray software (SAM, version 2.20) [19] with One Class response type (FDR<0.01). Differentially expressed genes were chosen if they fit at least one of the following criteria: 1) genes were regulated in at least one time point by either GBE or lovastatin, 2) genes were differentially expressed between GBE and lovastatin treatment in at least one time point, or 3) gene expression levels were different among the different time points for either GBE or lovastatin. A total of 1264 regulated genes/ESTs were selected out and presented using a component plane presentation integrated self-organizing map (CPP-SOM) [20] with 12 neurons based on the gene expression profile. The online database KEGG (www.genome.jp/kegg) was applied to interpret the gene function pathway.
Real-time RT-PCR
Total RNA from each sample used for the microarray experiment was subjected to reverse transcription. Real-time RT-PCR was conducted using an ABI PRISM 7300 Sequence Detector (Applied Biosystems) with SYBR green I fluorescent dye (Toyobo, Japan). The reactions were carried out in triplicate. GAPDH was used as an internal control. Gene expression was evaluated with threshold cycles. The gene names and PCR primer sequences are listed in Table S1 .
Western blot analysis
Proteins were prepared with the Mammalian Cell Extraction Kit (BioVision). An aliquot of each sample (50 µg) was subjected to SDS-polyacrylamide (10%) gel electrophoresis and electro-transferred onto a PVDF membrane. After being blocked with 5% nonfat milk, the membranes were individually probed with the following primary antibodies for 2 h: ABCA1  NM_005502  AAGCTCTTTGCACTAGGATGGC  TGTAGCATGTTCCGGTGTTTCTC  P  ND  ABCG5  NM_022436  GACTGCTCTGAACGTCTGAAATG  TTTCCAAATAACCACATGTCCC  NA  ABCG8  NM_022437  TCCTGCGGTGGTGTTTTG  CGATGAGGTAGATGGCGTA  NA  APOA1  NM_000039  ACCTAAAGCTCCTTGACAAC  CCTGCCACTTCTTCTGGA  P  R  APOB  NM_000384  AAGAACCTGTTAGTTGCTCTTAAGG  TTCTTCGTCGCAATGGCCT  NA  CYP7A1  NM_000780  GGATGTATTCTTTCTGCTACCGAG  CGCAGTCCTGAACATGTGAA  NA  DAF  NM_000574  TTTAAAATGGTCCACAGCAGTC  ATAATATGCCACCTGGTACATC  NA  DHCR7  NM_001360  AGTCACCTTTACTAGTCCTTTGG  GTAAATGCAGCCTAATGACAG  P  R  ELOVL6  NM_024090  TGCACTGGTATCACCACATCAC  TGCACGCCATAGTTCATAGTCA  P  R  NR1H4  NM_005123  TTTTGACGGAAATGGCAACC  TCAGAATGCCCAGACGGAAG  P  GAPDH  NM_002046  TGACTTCAACAGCGACACCCA  CACCCTGTTGCTGTAGCCAAA  P  IC  HMGCR  NM_000859  TAGGAGGCTACAACGCCCAT  CCACCCACCGTTCCTATCTC  P  R  IDI1  NM_004508  GGCTGAAAGCTGAGCTAGGA  TTTCATGTTCACCCCAGATAC  P  R  IGFBP1  NM_000596  TGCCAAACTGCAACAAGAATG  TGGAGACCCAGGGATCCT  P  R  INSIG2  NM_016133  AATGGCAACCAGCACCTC  CATGCACAGACACATTCTCTC  NA  KIAA0101  NM_014736  AACTCCCAAGTGGCAAAAAGG  TGTGTGATCAGGTTGCAAAGG  P  R  LDLR  NM_000527  GATTCATGTGGCAAGAACG  AGCTGAACTCACCGGATCG  P  ND  LRH1  NM_205860  TCGCCGATCAGAGCTCATA  CATTCCTCTCCATGTATCTTCTA  NA  LRP1  NM_002332  GCCTCCATCCTAATCCCTCT  GGTTTCCAATCTCCACGTTCA  P  ND  LXRA  NM_005693  GACTTTGCTAAACAGCTACCC  CTGCTTTGGCAAAGTCTTC  P  ND  MTTP  NM_000253  TATATGCAGTATGCTACCCACAGC  GTACCAAATGAGATTTGAGAGAGGT  P  ND  NPC1L1  NM_013389  CATCTCTATGGGAAGTGCGGT  CCACGTAGCTGAGGATGAC  P  ND  PCNA  NM_002592  ATAAAGAGGAGGAAGCTGTTAC  AGAGAGTGGAGTGGCTTTTG  P  R  SCAP  NM_012235  CCAGTGGAGGACAAGATGGG  CAGGTAAGGGAGGTGACAT  NA  SCARB1  NM_005505  CATGAAATCTGTCGCAGGC  TTTGGCAGATGACAGGGAC  NA  SHP  NM_021969  TGCCTGAAAGGGACCATC  ACTTCACACAGCACCCAGT  P  ND  SLC35B1  NM_005827  GGGTCTTGGTCTTGATGCC  CCAAGAGATGTCACTGTTTGA  P  R  SOAT1  NM_003101  GACTTGTCGTTACGTGTTTTAG  CAGTTTGGCTTCAAGTGAC  P  ND  SREBF2  NM_004599  TCACTCCCTGGGAAAGC . Then, the membranes were incubated with a horseradish peroxidase (HRP) conjugated secondary antibody, either goat anti-mouse (1:4000, Sigma) or donkey anti-goat (1:800, homemade). The membranes were visualized with ECL Plus reagent (GE Healthcare) and developed onto X-ray film (Kodak).
Results

Cholesterol lowering effect of GBE in hepatocytes
To determine whether GBE modulates cholesterol levels in hepatocytes, HepG2, and SK-HEP-1 cells were cultured in medium with or without various concentrations of either GBE or lovastatin (positive control). The total cholesterol content was measured using a colorimetric assay. After 24 h of treatment, GBE decreased the total cholesterol content in a dosedependent manner in both HepG2 and SK-HEP-1 cells. Lovastatin (0.5 µmol/L) also decreased the total cholesterol content ( Figure 1A , 1B). In HepG2 cells, both 0.5 µmol/L of lovastatin and 200 µg/mL of GBE demonstrated a time-dependent effect on cholesterol content. The maximum cholesterol reduction was observed at 24 h, whereas a moderate recovery was observed after 48 h ( Figure 1C, 1D ).
Inhibition of HMG-CoA reductase activity
To test whether GBE affects the activity of HMG-CoA reductase, the rate limiting enzyme in cholesterol biosynthesis, we performed an experiment using in vitro reacted hepatic microsomes. The activity of HMG-CoA reductase was inhibited by both GBE and lovastatin. A dose of 129 nmol/L of lovastatin inhibited the HMG-CoA reductase activity by 25.2%. GBE inhibited HMG-CoA reductase activity by 6.2%, 16% and 71.6% at concentrations of 32.26, 322.6, and 3226 µg/mL, respectively ( Table 1) .
Effect of GBE on cholesterol fluxes in HepG2 cells
We determined the effect of GBE on cholesterol flux. In HepG2 cells, lovastatin induced a significant increase in cholesterol influx. In contrast, GBE inhibited cholesterol influx in a dose-dependent manner ( Figure 2A ). No significant alterations in cholesterol efflux were observed in HepG2 cells treated with either GBE or lovastatin ( Figure 2B ).
Transcriptomic profiling induced by GBE in HepG2 cells
To determine the mechanisms underlying the effect of GBE on cholesterol lowering, we performed microarray analysis. The global transcriptomic profiling of the cells treated with either GBE or lovastatin is shown with PCA plots. We identified 1264 regulated genes/ESTs, which are shown as PCA and CPP-SOM ( Figure 3A , 3B, www.shbiochip.com/ research/GBE/HepG2). These results demonstrate a similar gene expression profile regulation of both GBE and lovastatin.
With ontology annotations, 254 of the regulated genes were Figure 3C ), fibrinogenesis, trafficking, and metabolism ( Figure S1 ). Detailed information on the regulated genes is provided in the supplementary material. Real-time RT-PCR was conducted on eight genes. GAPDH was used as an internal control because it was not modulated by GBE or lovastatin based on both the microarray and the semi-quantitative RT-PCR data (data not shown). The RT-PCR results demonstrated consistency with the microarray data ( Figure  S2 ). We further distinguished the differential regulation between GBE and lovastatin treatment of 228 of the regulated genes/ ESTs for at least one time point (Table S2) . Of these 228 genes, a potential target of GBE and lovastatin could be identified and the different mechanisms of the two drugs could be derived. For example, the fibrinogen A gene (FGA) was significantly downregulated at an early time point with GBE, but not with lovastatin. Furthermore, CYP1A1 was upregulated earlier and more strongly with GBE treatment compared with lovastatin treatment. In addition, TGFBR3 was gradually upregulated by GBE but not regulated by lovastatin.
Regulation of the cholesterol metabolism pathway Transcriptomic profiling revealed that GBE induced a significant change in the expression of genes in the cholesterol metabolic pathway. Genes involved in cholesterol biosynthesis, such as HMG-CoA reductase (HMGCR), isopentenyldiphosphate delta isomerase 1 (IDI1), sterol O-acyltransferase (SQLE), HMG-CoA synthase 1 (HMGCS1), farnesyl-diphosphate farnesyltransferase 1 (FDFT1), farnesyl-diphosphate synthase (FDPS) and lanosterol synthase (LSS), were consistently upregulated ( Figure 3C and Figure S3) . NR1H4, which encodes the transcription factor farnesoid X receptor (FXR), was downregulated by both GBE and lovastatin. Additionally, transcriptomic profiling revealed that GBE downregulates genes associated with cholesterol uptake, including scavenger receptor class F member 2 (SCARF2), Niemann-Pick type C1 (NPC1) and LDL receptor-related protein 10 (LRP10) ( Figure  3C ).
We further examined 20 cholesterol metabolism-related genes by real-time RT-PCR. We identified that the mRNA levels of HMGCR and SREBF2 (encoding sterol regulatory element-binding protein 2) were upregulated by GBE. On the other hand, the mRNA level of the SREBF chaperone (SCAP) Figure 4 . Examination of the cholesterol metabolism related genes with real-time PCR. GAPDH was used as an internal control. Gene expression was calculated with threshold cycles, the expression of each gene in the control group was set to 1. n=3. Data are presented as the relative average±SD.
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Xie ZQ et al Acta Pharmacologica Sinica npg was downregulated by GBE ( Figure 4A ). The protein level of both HMGCR and SREBF2 encoding protein SREBP2 was also increased ( Figure 5 ). Interestingly, insulin-induced gene 2 (INSIG2) was upregulated by GBE, but downregulated by Figure S1 . Functional categories of the representative genes that were regulated by GBE50 and lovastatin in HepG2 cells. Functional features of each gene were determined based on its ontology annotation and published literature. All the relevant genes are grouped by hierarchical clustering based on the expression regulation (log2ratios) across all the samples (www.shbiochip.com/research/GBE/HepG2). Log2 ratios were color coded as indicated.
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Acta Pharmacologica Sinica npg lovastatin. GBE and lovastatin had similar regulatory effects on several genes involved in cholesterol catabolism. CYP7A1 (encoding cholesterol 7-alpha-hydroxylase) was upregulated by treatment with both drugs. Genes encoding the transcription factors liver X receptor alpha (LXRA), farnesoid X receptor (FXR), orphan nuclear receptor (SHP), and liver receptor homolog 1 (LRH-1) were all downregulated by GBE and lovastatin. Sterol O-acyltransferase (SOAT1) was not significantly regulated by treatment with either GBE or lovastatin ( Figure 4B) .
Genes involved in cholesterol influx, such as the LDL receptor (LDLR), the scavenger receptor class B member 1 (SCARB1) and Niemann-Pick C1-like protein 1 (NPC1L1), were all upregulated by GBE and lovastatin. However, LDL-related protein 1 (LRP1) was downregulated. Lovastatin upregulated LDLR, but downregulated LRP1 expression to a greater extent than GBE ( Figure 4C ). Cholesterol efflux-related genes, such as transporter genes, ATP-binding cassette 1 (ABCA1), ATPbinding cassette 5 (ABCG5), ATP-binding cassette 8 (ABCG8), microsomal triglyceride transfer protein (MTTP) and apolipoprotein B 100 (APOB100), were not significantly regulated. However, the cholesterol efflux gene apolipoprotein A-I (APOA1) was upregulated by both GBE and lovastatin ( Figure  3D, Figure 6 ). 
Discussion
In the present study, the cholesterol lowering effect of GBE was demonstrated in cultured hepatocytes. We used lovastatin as a positive control because it functions as an HMGCoA reductase inhibitor. Here, we demonstrate that GBE also inhibits the activity of HMG-CoA reductase in an in vitro enzymatic activity assay using hepatic microsomes. Based on the claim that flavonoids possess a blood cholesterol levellowering effect by inhibiting HMG-CoA reductase activity [21] and the major component of GBE is flavonoids (~24%), it is likely that the flavonoids in GBE contribute to its cholesterollowering effect. However, the exact active components in GBE that are involved in lowering cellular cholesterol are not precisely known. Based on the pleiotropic effects of GBE, we used transcriptomic profiling analysis to allow us to assess multiple genes simultaneously. We propose that this approach is essential for understanding the complex mechanisms of phytomedicines. Previous studies have widely used transcriptomic strategies to explore drug regulation networks [22, 23] . In the current study, transcriptomic profiling revealed that GBE induces significant gene expression changes in cultured hepatocytes. These data broadened our understanding of the molecular mechanisms by which GBE exerts its pleiotropic effects. In particular, our study focused on defining the molecular mechanisms by which GBE treatment modulates the genes involved in cholesterol metabolism.
Cholesterogenic genes are predominantly regulated through a feedback mechanism involving the cellular cholesterol pool. In this study, we show that GBE and lovastatin both lower cellular cholesterol by inducing an adaptive response in gene expression changes. Most members of the cholesterol biosynthesis pathway were increased. Additionally, we observed upregulation of SREBF2, a ubiquitously expressed transcription factor that controls cholesterol homeostasis by stimulating the transcription of sterol-regulated genes [24] . Thus, the observed upregulation of SREBF2 and cholesterogenic genes suggests that GBE lowers cholesterol through an adaptive response. In addition INSIG2, an endoplasmic reticulum protein that binds SCAP and blocks the export of SREBPs to the Figure S3 . Genes involved in the cholesterol biosynthesis pathway were upregulated by GBE50 and/or lovastatin. Genes in red were observed to be over expressed, while the genes in light green indicate no significant changes. Symbol   AI335447  ABCB6  NM_013375  ABT1  NM_005891  ACAT2  NM_001096  ACLY  NM_001096  ACLY  NM_022977  ACSL4  BC006121  AIFM2  NM_020299  AKR1B10  NM_002860  ALDH18A1  AK026685  AMMECR1L  NM_001145  ANG  U79297  ANKRD46  AK001472  ANLN  NM_001153  ANXA4  NM_001641  APEX1  NM_001643  APOA2  NM_001643  APOA2  NM_019101  APOM  NM_004044  ATIC  NM_005504  BCAT1  AB067490  C14orf106  NM_031210  C14orf156  NM_001735  C5  BG216972  C6orf182  AL133014  C7orf20  AF086300  CACNG1  NM_004343  CALR  AL122079  CCDC14  NM_004701  CCNB2  NM_004354  CCNG2  NM_001786  CDC2  NM_005195  CEBPD  NM_018132  CENPQ  NM_000204  CFI  BC001425  CKS1B  NM_001856  COL16A1  AK024070  CTPS2  NM_001908  CTSB  NM_030579  CYB5B  NM_000499  CYP1A1  NM_018122  DARS2  NM_006716  DBF4  NM_014762  DHCR24  BC007339  DHRS2  NM_016306  DNAJB11  U97105  DPYSL2  NM_012145  DTYMK  NM_004428  EFNA1  NM_012199  EIF2C1  NM_003750  EIF3A  NM_004433  ELF3  NM_003633  ENC1  NM_014805  EPM2AIP1  NM_001981  EPS15  NM_001982  ERBB3  AF086028  ERBB3  AL512760  FADS1   Genbank  Symbol   BC008360  FAM113B  AB046794  FAM29A  NM_012300  FBXW11  NM_004462  FDFT1  R82935  FDPS  NM_002004  FDPS  NM_021871  FGA  NM_005130  FGFBP1  NM_004497  FOXA3  AF146696  FOXP1  NM_031904  FRMD8  BC006997  G3BP1  NM_000512  GALNS  NM_000821  GGCX  NM_005271  GLUD1  NM_006578  GNB5  NM_002106  H2AFZ  NM_005327  HADH  NM_003512  HIST1H2AC  NM_002129  HMGB2  NM_000859  HMGCR  XM_048933  HMGCS1  NM_005517  HMGN2  NM_012484  HMMR  NM_020995  HPR  NM_003299  HSP90B1  X87949  HSPA5  NM_002157  HSPE1  NM_006389  HYOU1  BC002640  IFT20  NM_000883  IMPDH1  NM_014869  IQSEC1  AL049321  IRAK1BP1  NM_033666  ITGB1  NM_002217  ITIH3  BG035179  KCTD11  AB006624  KIAA0286  AL390128  KIAA1530  AB051499  KIAA1712  NM_014875  KIF14  NM_012310  KIF4A  NM_002266  KPNA2  NM_002296  LBR  NM_005566  LDHA  NM_000235  LIPA  M94362  LMNB2  U28831  LOC400986  NM_002358  MAD2L1  NM_032844  MASTL  NM_002388  MCM3  NM_002388  MCM3  NM_016011  MECR  NM_004994  MMP9  NM_005591  MRE11A  NM_000251  MSH2  NM_002455  MTX1  NM_014865 NCAPD2 Table S2 . List of genes with different regulations with GBE and lovastatin.
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Cholesterol 7-alpha-hydroxylase (CYP7A1) is the ratelimiting enzyme that converts cholesterol to bile acids. The oxysterol receptor, liver X receptor alpha (LXRA), is the dominant regulator of CYP7A1 transcription [26] . The bile acid receptor, FXR, is activated by bile acids and subsequently represses CYP7A1 expression through a regulatory cascade involving SHP and LRH-1 [27] . In this study, LXRA, FXR, SHP, and LRH-1 were consistently downregulated by both GBE and lovastatin. Interestingly, CYP7A1 was upregulated by both cholesterollowering agents. Although CYP7A1 was upregulated, we propose that the catabolism of cholesterol to bile acids might be diminished because both the bile acid biosensor, FXR, and the dominant regulator were downregulated.
As a feedback response to the cellular cholesterol-lowering effects, lovastatin induced the overexpression of LDLR and SCARBI. LDLR, the LDL receptor, is involved in receptormediated endocytosis of LDL and is regulated by SREBP2 [28] . SCARBI (Scavenger receptor class B type I) is a high-density lipoprotein (HDL) receptor in the liver and is involved in the selective uptake of cholesteryl ester from HDL that is involved in the reverse cholesterol transport (RCT) [29] . Thus, the overexpression of LDLR and SCARBI could facilitate cholesterol uptake from the medium to maintain the homeostasis of the cellular cholesterol pool. However, we found that GBE inhibits the uptake of cholesterol from the medium. This result is consistent with a previous study by Qiu et al, in which GBE inhibited the hyperpermeability of endothelial cells to [
125 I]-labeled oxLDL [30] . The mild upregulation of LDLR and the strong downregulation of LRP1 and LRP10 indicate that GBE is a cholesterol uptake inhibitor, although the exact mechanisms by which GBE inhibits cholesterol uptake were not identified. The liver is largely responsible for maintaining cholesterol homeostasis. In the present study, we find that GBE inhibits cholesterol influx in HepG2 cells. These data imply that cholesterol clearance from the blood into the liver might be restrained. Although the cellular global HMG-CoA reductase activity in cells was not pursued in this study, the in vitro inhibition of HMG-CoA reductase activity suggests an attenuation of endogenous cholesterol biosynthesis. This was in agreement with our previous findings that GBE mildly inhibits the elevation of blood cholesterol levels and liver lipid accumulation induced by high-fat diet in rats [31] .
In conclusion, both GBE and lovastatin lowered the cholesterol content in cultured hepatocytes. GBE exhibited dual effects on both HMG-CoA reductase activity and cholesterol influx inhibition. The proposed similar and unique mechanisms of cholesterol lowering by GBE and lovastatin are summarized in Figure 6 . Further investigation of the genes regulated by GBE is of particular importance both for understanding the unique mechanisms by which GBE regulates cholesterol metabolism and for the clinical application of GBE. The genes in green were down-regulated, while the genes in red were over-expressed, the yellow color represents genes that were not significantly changed, the red arrows indicated stimulation, the green line with block represents negative regulation. The following theme is proposed: lovastatin lowers cellular cholesterol content by inhibiting de novo biosynthesis by modulating the expression of the rate limiting enzyme, HMGCR, and inducing adaptive responses, such as the over expression of genes involved in cholesterol endogenous biosynthesis and cholesterol influx, and the down-regulation of genes related to cholesterol catabolism into bile acids, which are required for the maintenance of the homeostasis of cellular cholesterol. With respect to molecular mechanisms downstream of GBE treatment, in addition to inhibiting HMGCR, cholesterol influx was also inhibited and related gene expression changes were demonstrated. 
Supplementary material
Transcriptome regulations with GBE50 and lovastatin in HepG2 cells
Among the regulated genes with ontology annotations, 254 were assigned into groups based on their biological functions ( Figure  S1 ).
Lipid metabolism pathways were affected by both drugs
Most members of the cholesterol biosynthesis pathway were upregulated in both treatment groups, including the rate limiting enzyme, 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), isopentenyl-diphosphate delta isomerase 1 (IDIl), squalene epoxidase (SQLE), 3-hydroxy-3-methylglutaryl-coenzyme A synthase 1 (HMGCS1), farnesyl-diphosphate farnesyltransferase 1 (FDFT1), farnesyl-diphosphate synthase (FDPS), lanosterol synthase (LSS), etc. Genes involved in cholesterol uptake, such as the scavenger receptor class F member (SCARF2) and Niemann-Pick disease-type C1 (NPC1) were downregulated in both treatment groups. The cellular cholesterol content sensing transcription factor, farnesoid X receptor (FXR) (NR1H4), was observed to be down regulated. The genes encoding the fatty acid metabolism enzymes were also significantly regulated. Acyl-CoA synthetase (ACSS2), stearoyl-CoA desaturase (SCD), hydroxyacylcoenzyme A dehydrogenase (HADH), fatty acid desaturase 2 (FADS2) and 3-oxoacid CoA transferase 2 (OXCT2) were upregulated in both treatment groups. However, fatty-acid-coenzyme A ligase (FACL2), fatty acid desaturase 3 (FADS3), as well as low density lipoprotein receptor-related protein 10 (LRP10), were more strongly downregulated by GBE50 than lovastatin.
Regulations of transporters with two drugs
Downregulation of the solute carrier proteins (SLC1A5, SLC2A3, SLC4A5, SLC7A1, SLC7A2, SLC7A11, SLC35B1, SLC38A2, SLC43A1), and the translocase of inner mitochondrial membrane 9 (TIMM9) revealed that cellular substance intracellular trafficking was inhibited by the both drugs. Additionally, our microarray analysis revealed that the exocyst complex component 5 (EXOC5), which is essential for post-Golgi traffic, was upregulated.
Regulation of energy metabolism related genes
The acute repression of mitochondrial H + transporting ATP synthase subunit (ATP5H) was detected as early response to the treatment with both GBE and lovastatin; however, the expression levels were recovered to a normal level when treated for 24 h, suggesting that energy metabolism was inhibited at an early stage when treated with either drug, but the effect only lasted for a short period. Similarly, carbohydrate metabolism-associated genes, including lactate dehydrogenase A (LDHA), aldehyde dehydrogenase member (ALDH18A1), nucleic acid metabolism related uracil-DNA glycosylase (UNG), inosine monophosphate dehydrogenase (IMPDH1), etc, were upregulated. Downregulation of glutamicoxaloacetic transaminase (GOT1), methylenetetrahydrofolate dehydrogenase 2 (MTHFD2), arginase (AARG2) suggested that these drugs also inhibited amino acid metabolism. The downregulation of monoamine oxidase A (MAOA) is associated with a neurotransmitter degradation reduction. The early upregulation of carbonyl reductase 4 (CBR4), aldolase A (ALDOA), aldose reductase (AKR1B10) and vascular adhesion protein 1 (amine oxidase, copper containing 3) (AOC3) by only GBE50 suggests that these genes are not regulated by lovastatin.
Cell signaling and communication gene expression regulations
The expression of cell-cell communication and signaling genes, including oligodendrocyte myelin glycoprotein (OMG) and Vav 2 oncogene (VAV2), were upregulated by both drugs at an early time point and the effects lasted at least 24 h. Serum/glucocorticoid regulated kinase (SGK) and transforming growth factor, beta receptor III (TGFBR3), fibroblast growth factor binding protein 1 (FGFBP1), and adenylate cyclase-associated protein 1 (CAP1) were upregulated with GBE50 treatment, but were either not regulated or regulated at a late time point by lovastatin treatment. Expression of the PDZ domain containing protein coding gene (PDZD3) was down regulated at earliest time point in both treatment groups, and was observed to rapidly recover to normal levels in the GBE50 treatment group, but remained repressed with lovastatin treatment. It is important to point out that the iron metabolism members, ceruloplasmin (ferroxidase) (CP) and transferrin (TF), were both rapidly upregulated by GBE50, but only slightly regulated at 24 h with lovastatin, and the downregulation of a calcium binding protein, nucleobindin 2 (NUCB2), occurred later with lovastatin than with GBE.
